Compare OSPN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | DCTH |
|---|---|---|
| Founded | 1991 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.7M | 578.4M |
| IPO Year | 2000 | 2015 |
| Metric | OSPN | DCTH |
|---|---|---|
| Price | $18.23 | $15.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $18.00 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 491.9K | 306.8K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | 28.77 | ★ 107.53 |
| EPS | ★ 0.48 | 0.04 |
| Revenue | ★ $243,180,000.00 | N/A |
| Revenue This Year | $2.90 | $24.61 |
| Revenue Next Year | $2.36 | $24.27 |
| P/E Ratio | ★ $37.52 | $376.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $8.12 |
| 52 Week High | $18.83 | $17.42 |
| Indicator | OSPN | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 43.91 |
| Support Level | $17.05 | $9.98 |
| Resistance Level | $18.28 | $16.51 |
| Average True Range (ATR) | 0.54 | 0.53 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 67.61 | 39.01 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.